Top Stories
PNB Q4 Results: Profit jumps 14%, GNPA improves, but NII slips Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market LTM, Uniphore join hands to build industry-specific AI solutions for enterprises Lupin secures USFDA approval for rare disease drug with $337 million opportunity IndiGo turmoil deepens: Another top executive quits after CEO exit Exide Industries Q4 Results: Net profit jumps 22% YoY, auto OEM growth drives strong earnings Godrej Properties Q4 Results: Net profit jumps 68% YoY; Guides for above 20% growth in FY27 BHEL Q4 FY26 Results: Net profit jumps over 150% YoY; EBITDA more than doubles on strong execution PNB Q4 Results: Profit jumps 14%, GNPA improves, but NII slips Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market LTM, Uniphore join hands to build industry-specific AI solutions for enterprises Lupin secures USFDA approval for rare disease drug with $337 million opportunity IndiGo turmoil deepens: Another top executive quits after CEO exit Exide Industries Q4 Results: Net profit jumps 22% YoY, auto OEM growth drives strong earnings Godrej Properties Q4 Results: Net profit jumps 68% YoY; Guides for above 20% growth in FY27 BHEL Q4 FY26 Results: Net profit jumps over 150% YoY; EBITDA more than doubles on strong execution
TAG

# Rajesh Kumar Rathanchand